SI-BONE stock eases below 19 dollars as investors eye recent growth figures

Published on 09/02/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SI-BONE stock is trading just under 19 dollars on Nasdaq while investors weigh the company’s latest revenue growth and margin trends from recent quarterly results.

SIBN, US8255921098, Illustration mit AI erstellt.

SI-BONE stock (ISIN US8255921098) is trading around 18.88 US dollars on Nasdaq as of September 1, 2026, leaving the shares slightly lower on the day but still in the high-teens price range according to market data from a major US stock portal.

Recent performance and growth metrics

In its most recent reported quarter, SI-BONE, Inc. highlighted solid revenue growth compared with the prior-year period, with sales increasing by a double-digit percentage and helping to narrow operating losses versus the same quarter a year earlier, based on data compiled by analysts from recent company filings.

According to these compiled figures, quarterly revenue for SI-BONE reached a level that was notably higher than in the corresponding period of the previous year, illustrating that the company has been expanding its top line at a healthy pace while also improving gross margin and operating efficiency over time.

Market context and investor focus

With SI-BONE stock quoted at about 18.88 US dollars on September 1, 2026, the shares remain below a previously reported 52-week high but clearly above lows seen earlier in the 52-week range, indicating that the market continues to give the company a mid-cap style valuation in the medical technology segment.

For investors, one focal point is how SI-BONE can convert its revenue growth into sustainable profitability, including progress in reducing operating losses and managing cash flow, as the company invests in sales expansion and product development for its sacroiliac joint fusion solutions.

Go deeper

More on SI-BONE stock and filings

For additional background on SI-BONE stock, including further figures from recent reports and regulatory filings, the overview at ad-hoc-news.de and the company’s own investor materials provide a deeper quantitative picture.

All news on this ISIN Investor Relations

Core product and business model

SI-BONE, Inc. focuses on minimally invasive surgical solutions for sacroiliac joint dysfunction, with its iFuse Implant System representing a key product that supports revenue growth by addressing chronic lower back and pelvic pain in patients who do not respond adequately to conservative treatments.

Stock level and investor view

As of September 1, 2026, SI-BONE stock at around 18.88 US dollars on Nasdaq reflects a valuation that balances its continuing revenue growth against the company’s path toward sustained profitability, offering investors a medical technology exposure linked to sacroiliac joint fusion and related orthopedic innovations.